Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.
Also called NCT06399835
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 120 participants
- Registry
-
NCT06399835
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT06399835. Randomized; no masking; primary purpose treatment. Start 2024-02-01 (actual); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Enavogliflozin
- Intervention (Drug)
- Pioglitazone
- Lead sponsor
- Seoul National University Bundang Hospital
- Collaborator
- Daewoong Pharmaceutical Co. LTD.
Record details
- Record id
cardio:ct-nct06399835- Content hash
721370cafd06d4a426901ba0ee530c888118bbbc409d8c4a76bdff3764c2b1e1